Arrowgrass Capital Partners (US)’s AbbVie ABBV Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$8.85M	Sell	100,000 -62,500	-38%	-$5.19M	2.33%	10
2019 Q3	$12.3M	Hold	162,500	–	–	0.91%	27
2019 Q2	$11.8M	Hold	162,500	–	–	0.28%	100
2019 Q1	$13.1M	Buy	162,500 +62,500	+63%	+$5.11M	0.39%	81
2018 Q4	$9.22M	Buy	+100,000	New	+$8.79M	0.34%	91
2018 Q1	–	Sell	-189,800	Closed	-$18.4M	–	136
2017 Q4	$18.4M	Buy	189,800 +187,902	+9,900%	+$17.7M	0.18%	140
2017 Q3	$16.9M	Sell	1,898 -1,261	-40%	-$96K	0.12%	200
2017 Q2	$22.9M	Sell	3,159 -1,046	-25%	-$70.3K	0.17%	156
2017 Q1	$27.4M	Sell	4,205 -1,526	-27%	-$95.9K	0.28%	95
2016 Q4	$35.9M	Buy	5,731 +1,154	+25%	+$70.4K	0.41%	56
2016 Q3	$28.9M	Buy	4,577 +843	+23%	+$54.6K	0.39%	63
2016 Q2	$23.1M	Sell	3,734 -1,706	-31%	-$104K	0.25%	63
2016 Q1	$31.1M	Buy	5,440 +765	+16%	+$42.6K	0.37%	49
2015 Q4	$27.7M	Buy	4,675 +2,680	+134%	+$154K	0.34%	39
2015 Q3	$10.9M	Buy	1,995 +1,225	+159%	+$79.7K	0.2%	87
2015 Q2	$5.17M	Buy	770 +570	+285%	+$37.2K	0.08%	210
2015 Q1	$1.17M	Buy	+200	New	+$12.1K	0.02%	318
2014 Q4	–	Sell	-150,000	Closed	-$8.66M	–	420
2014 Q3	$8.66M	Buy	+150,000	New	+$8.33M	0.21%	77

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ABBV Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) reduced its AbbVie (ABBV) stake by 57% in Q4 2019, selling an estimated $7.31M and leaving 65,970 shares worth $5.84M. The position accounts for 1.54% of the portfolio, ranked #24.

Arrowgrass Capital Partners (US) first reported a position in ABBV in Q1 2015 and has held it in 14 quarters since. The position peaked at $11.7M in Q3 2019. 2,244 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

Arrowgrass Capital Partners (US) held 65,970 shares of AbbVie worth $5.84M as of Q4 2019.
Arrowgrass Capital Partners (US) sold 88,100 AbbVie shares in Q4 2019, an estimated $7.31M.
AbbVie made up 1.54% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #24 holding.
Arrowgrass Capital Partners (US) first reported a position in AbbVie in Q1 2015 and has held it in 14 quarters since.
Arrowgrass Capital Partners (US)'s AbbVie position peaked at $11.7M in Q3 2019.
2,244 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.